



Editorial

Bioactive Oxadiazoles 3.0

Antonio Palumbo Piccionello

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, Italy; antonio.palumbopiccionello@unipa.it

Heterocycles are fundamental moieties for the construction of new compounds with perspective applications ranging from drugs to materials [1–4].

In this wide panorama we focused our attention to the sub-class of Oxadiazoles. Oxadiazoles are electron-poor five-membered aromatic heterocycles that contain one oxygen and two nitrogen atoms. The oxadiazoles, namely 1,2,3-, 1,2,4-, 1,2,5-, and 1,3,4-regioisomers, together with *N*-oxides, benzo-fused, and non-aromatic derivatives, present a wide application range from material science to explosives and bioactive compounds [5–8]. In the latter field, there are many possibilities, and oxadiazoles have been revealed to be active as antitumoral agents [5,9], neuroprotective compounds [10], antimicrobials [8,11], among others.

Some bioactive oxadiazoles have reached the market or are in the advanced clinical trials stage, such as oxolamine, ataluren, raltegravir, capeserod, azilsartan, furazabol, sydnophen, zibotentan, opicabone, etc. Moreover, the oxadiazole skeleton is also present in some natural compounds, such as phidianidine and quisqualic acid, providing new inspiration for the synthesis of bio-inspired drugs. Another important issue is the use of oxadiazoles in medicinal chemistry as amide and ester isosters and as peptido-mimetics, offering a well-established tool for drug design. All of these aspects have increased interest in these heterocycles, increasing the impact of oxadiazoles in the field of bioactive compounds. This Special Issue is the continuation of our previous Special Issues “Bioactive Oxadiazoles” [12] and “Bioactive Oxadiazoles 2.0” [13] and is intended to offer a wide panorama of the potential applications of these compounds toward all diseases.

The research fields explored in this Special Issue include the discovery of new compounds with various biological activities such as: antibacterial 1,2,4-oxadiazole derivatives [14], antiplasmodial 1,2,5-oxadiazoles [15], 1,2,4-oxadiazole derivatives as nematocides [16] and 1,3,4-oxadiazoles with anticancer activity [17]. Moreover, the synthetic accessibility of bioactive 1,2,4-oxadiazoles at room temperature, was reviewed [18]. These researches are just some examples of the fascinating and expanding field of oxadiazoles' chemistry, that represent an emerging field with growing potential.

Conflicts of Interest: The author declares no conflicts of interest.



Citation: Palumbo Piccionello, A. Bioactive Oxadiazoles 3.0. *Int. J. Mol. Sci.* **2024**, *25*, 6027. <https://doi.org/10.3390/ijms25116027>

Received: 27 May 2024

Accepted: 29 May 2024

Published: 30 May 2024



Copyright: © 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

References

1. Kerru, N.; Gummidi, L.; Maddila, S.; Gangu, K.K.; Jonnalagadda, S.B. A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications. *Molecules* **2020**, *25*, 1909. [CrossRef] [PubMed]
2. Rizzo, C.; Amata, S.; Pibiri, I.; Pace, A.; Buscemi, S.; Palumbo Piccionello, A. FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022. *Int. J. Mol. Sci.* **2023**, *24*, 7728. [CrossRef] [PubMed]
3. Hirai, M.; Tanaka, N.; Sakai, M.; Yamaguchi, S. Structurally constrained boron-, nitrogen-, silicon-, and phosphorus-centered polycyclic π -conjugated systems. *Chem. Rev.* **2019**, *119*, 8291–8331. [CrossRef] [PubMed]
4. Rizzo, C.; Pace, A.; Pibiri, I.; Buscemi, S.; Palumbo Piccionello, A. From Conventional to Sustainable Catalytic Approaches for Heterocycles Synthesis. *ChemSusChem* **2024**, *17*, e202301604. [CrossRef] [PubMed]
5. Benassi, A.; Doria, F.; Pirota, V. Groundbreaking Anticancer Activity of Highly Diversified Oxadiazole Scaffolds. *Int. J. Mol. Sci.* **2020**, *21*, 8692. [CrossRef] [PubMed]
6. Salassa, G.; Terenzi, A. Metal Complexes of Oxadiazole Ligands: An Overview. *Int. J. Mol. Sci.* **2019**, *20*, 3483. [CrossRef] [PubMed]
7. Campofelice, A.; Lentini, L.; Di Leonardo, A.; Melfi, R.; Tutone, M.; Pace, A.; Pibiri, I. Strategies against Nonsense: Oxadiazoles as Translational Readthrough-Inducing Drugs (TRIDs). *Int. J. Mol. Sci.* **2019**, *20*, 3329. [CrossRef] [PubMed]
8. Glomb, T.; Świątek, P. Antimicrobial Activity of 1,3,4-Oxadiazole Derivatives. *Int. J. Mol. Sci.* **2021**, *22*, 6979. [CrossRef] [PubMed]
9. Caruso Bavisotto, C.; Nikolic, D.; Marino Gammazza, A.; Barone, R.; Lo Cascio, F.; Mocchiato, E.; Zummo, G.; Conway de Macario, E.; Macario, A.J.L.; Cappello, F.; et al. The dissociation of the Hsp60/pro-Caspase-3 complex by bis(pyridil)oxadiazole copper complex (CubipyOXA) leads to cell death in NCI-H292 cancer cells. *J. Inorg. Biochem.* **2017**, *170*, 8–16. [CrossRef] [PubMed]
10. Mangione, M.R.; Palumbo Piccionello, A.; Marino, C.; Ortore, M.G.; Picone, P.; Vilasi, S.; Di Carlo, M.; Buscemi, S.; Bulone, D.; San Biagio, P.L. Photo-inhibition of A β fibrillation mediated by a newly designed fluorinated oxadiazole. *RSC Adv.* **2015**, *5*, 16540–16548. [CrossRef]
11. Li, P.; Tian, P.; Chen, Y.; Song, X.; Xue, W.; Jin, L.; Hu, D.; Yang, S.; Song, B. Novel bithioether derivatives containing a 1,3,4-oxadiazole moiety: Design, synthesis, antibacterial and nematocidal activities. *Pest. Manag. Sci.* **2018**, *74*, 844–852. [CrossRef] [PubMed]
12. MDPI. Available online: https://www.mdpi.com/journal/ijms/special_issues/oxadiazoles (accessed on 24 May 2024).
13. MDPI. Available online: https://www.mdpi.com/journal/ijms/special_issues/oxadiazoles_2 (accessed on 24 May 2024).
14. Amata, S.; Calà, C.; Rizzo, C.; Pibiri, I.; Pizzo, M.; Buscemi, S.; Palumbo Piccionello, A. Synthesis and Antibacterial Activity of Mono- and Bi-Cationic Pyridinium 1,2,4-Oxadiazoles and Triazoles. *Int. J. Mol. Sci.* **2024**, *25*, 377. [CrossRef] [PubMed]
15. Hohegger, P.; Hermann, T.; Dolensky, J.; Seebacher, W.; Saf, R.; Pferschy-Wenzig, E.-M.; Kaiser, M.; Mäser, P.; Weis, R. Structure–Activity Relationships and Antiplasmodial Potencies of Novel 3,4-Disubstituted 1,2,5-Oxadiazoles. *Int. J. Mol. Sci.* **2023**, *24*, 14480. [CrossRef] [PubMed]
16. Luo, L.; Ou, Y.; Zhang, Q.; Gan, X. Discovery of 1,2,4-Oxadiazole Derivatives Containing Haloalkyl as Potential Acetylcholine Receptor Nematicides. *Int. J. Mol. Sci.* **2023**, *24*, 5773. [CrossRef] [PubMed]
17. Strzelecka, M.; Glomb, T.; Drag-Zalesińska, M.; Kulbacka, J.; Szewczyk, A.; Sączko, J.; Kasperkiewicz-Wasilewska, P.; Rembiałkowska, N.; Wojtkowiak, K.; Jezierska, A.; et al. Synthesis, Anticancer Activity and Molecular Docking Studies of Novel N-Mannich Bases of 1,3,4-Oxadiazole Based on 4,6-Dimethylpyridine Scaffold. *Int. J. Mol. Sci.* **2022**, *23*, 11173. [CrossRef] [PubMed]
18. Baykov, S.V.; Shetnev, A.A.; Semenov, A.V.; Baykova, S.O.; Boyarskiy, V.P. Room Temperature Synthesis of Bioactive 1,2,4-Oxadiazoles. *Int. J. Mol. Sci.* **2023**, *24*, 5406. [CrossRef] [PubMed]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.